Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President and CEO · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,347,543 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,372,023 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,029 · Balance 1,369,994 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,297 · Balance 1,366,697 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,981 · Balance 1,362,716 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,143 · Balance 1,359,573 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,357 · Balance 1,356,216 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,266 · Balance 1,353,950 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,214 · Balance 1,352,736 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 2,010 · Balance 1,350,726 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 573 · Balance 1,350,153 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,358 · Balance 1,348,795 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 847 · Balance 1,347,948 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 405 · Balance 1,347,543 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy SMK Trust FBO KSK | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Krish Srinivas Krishnan Trust | 77,710 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 77,710 F17: Held by the Krish Srinivas Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Krish Srinivas Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,805 | $59.11 | $106,698.97 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892,763 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F8 · price: This transaction was executed in multiple trades ranging from $58.40 to $59.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,371 | $57.63 | $309,531.80 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894,568 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F7 · price: This transaction was executed in multiple trades ranging from $57.37 to $58.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,784 | $56.84 | $385,588.99 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899,939 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F6 · price: This transaction was executed in multiple trades ranging from $56.37 to $57.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,900 | $55.99 | $162,356.50 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,723 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F5 · price: This transaction was executed in multiple trades ranging from $55.36 to $56.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,552 | $59.03 | $622,874.01 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,909,623 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F4 · price: This transaction was executed in multiple trades ranging from $58.69 to $59.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 12,445 | $58.09 | $722,872.80 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920,175 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F3 · price: This transaction was executed in multiple trades ranging from $57.65 to $58.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,842 | $57.43 | $220,639.14 |
DisclosureSEC source: 0001209191-20-030562 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932,620 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F2 · price: This transaction was executed in multiple trades ranging from $56.65 to $57.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,906 | $62.38 | $181,267.27 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 9 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936,462 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F10 · price: This transaction was executed in multiple trades ranging from $62.07 to $63.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,561 | $61.52 | $219,075.92 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 8 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,368 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F9 · price: This transaction was executed in multiple trades ranging from $61.06 to $62.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,022 | $60.71 | $608,389.52 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,942,929 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F8 · price: This transaction was executed in multiple trades ranging from $60.06 to $61.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,192 | $59.60 | $130,634.43 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,952,951 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F7 · price: This transaction was executed in multiple trades ranging from $59.06 to $60.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,617 | $63.15 | $165,254.65 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,955,143 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F6 · price: This transaction was executed in multiple trades ranging from $63.00 to $64.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 16,033 | $62.70 | $1,005,208.17 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,957,760 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F5 · price: This transaction was executed in multiple trades ranging from $62.00 to $63.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 600 | $63.95 | $38,371.98 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973,793 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F4 · price: This transaction was executed in multiple trades ranging from $63.91 to $64.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,588 | $62.98 | $288,931.14 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974,393 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F3 · price: This transaction was executed in multiple trades ranging from $62.64 to $63.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,481 | $62.26 | $465,762.57 |
DisclosureSEC source: 0001209191-20-011211 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,978,981 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F2 · price: This transaction was executed in multiple trades ranging from $61.64 to $62.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 400 | $54.38 | $21,752.00 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 8 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,462 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F9 · price: This transaction was executed in multiple trades ranging from $54.35 to $54.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,082 | $53.86 | $112,140.27 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,862 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F8 · price: This transaction was executed in multiple trades ranging from $53.35 to $54.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,080 | $52.68 | $425,643.90 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,988,944 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F7 · price: This transaction was executed in multiple trades ranging from $52.31 to $53.215. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,513 | $51.82 | $544,743.71 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,997,024 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F6 · price: This transaction was executed in multiple trades ranging from $51.31 to $52.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,046 | $50.98 | $53,321.73 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007,537 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F5 · price: This transaction was executed in multiple trades ranging from $50.29 to $51.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,598 | $51.47 | $236,657.22 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,008,583 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F4 · price: This transaction was executed in multiple trades ranging from $51.235 to $51.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 11,386 | $50.69 | $577,159.76 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013,181 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F3 · price: This transaction was executed in multiple trades ranging from $50.16 to $51.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 11,895 | $49.72 | $591,469.36 |
DisclosureSEC source: 0001209191-19-057115 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,024,567 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F2 · price: This transaction was executed in multiple trades ranging from $49.16 to $50.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 21:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0001209191-18-055881 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036,462 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | OtherCommon Stock | 26,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035581 · doc4.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011,462 F1 · shares: Award of restricted stock. F1 · price: Award of restricted stock. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 20:43 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 50,000 | $11.00 | $550,000.00 |
DisclosureSEC source: 0000925421-18-000155 · edgar.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,985,249 Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | ConversionSeries A Convertible Preferred Stock · Derivative | 112,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000358 · edgar.xml · derivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 112,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | ConversionCommon Stock | 112,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000358 · edgar.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 112,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0000925421-17-000358 · edgar.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935,249 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.